Journal of Periodontal and Implant Science

Korean Academy of Periodontology (대한치주과학회)
권호 표지

The Effects of Alendronate on Healing of the Calvarial Defect in Rats

백서 두개골 결손부의 치유과정에 alendronate가 미치는 영향

  • Kim, Jae-Hyung (Department of Periodontology College of Dentistry Kyungpook National University) ;
  • Lee, Jae-Mok (Department of Periodontology College of Dentistry Kyungpook National University) ;
  • Park, Jin-Woo (Department of Periodontology College of Dentistry Kyungpook National University) ;
  • Suh, Jo-Young (Department of Periodontology College of Dentistry Kyungpook National University)
  • 김재형 (경북대학교 치과대학 치주과학교실) ;
  • 이재목 (경북대학교 치과대학 치주과학교실) ;
  • 박진우 (경북대학교 치과대학 치주과학교실) ;
  • 서조영 (경북대학교 치과대학 치주과학교실)
  • Published : 2004.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

The present study aimed to examine the effects of topical application of alendronate with a collagen membrane on the healing of the calvarial defect in rats, which has a good experimental design for the healing of tissue destruction, To study the effect of alendronate on bone healing, the collagen membrane containing $200{\mu}g$ alendronate was inserted in the defects of the right side and collagen membrane treated with physiologic saline was inserted in the defects of the left side. After 1, 2 and 4 weeks, observation of histologic feature after H&E staining, cell counting after TRAP staining, and hardness measurement(Knoop) were performed. In histologic finding, similar features were shown for both test and control groups each week. In cell counting only the 1 week test groups showed significant reduction of TRAP(+)cells than control groups(p<0.01) and the control groups showed statistically significant difference for 1, 2, 4weeks(p<0.05). In hardness measurement, The 2 week test groups showed significant higher hardness than control groups.(p<0,05) and not 4 weeks. There was significant increase of hardness for both groups as time goes by.(p<0.0l) Therefore local application of alendronate with collagen membrane was somewhat effective in reducing osteoclastic activity and increasing hardness in the early stage of healing. Further investigation concerning the actual effect of alendronate for bony healing will be necessary to apply the clinical cases

Bisphosphonates는 파골세포에 의한 골흡수를 방지하는 물질로 알려져 있으며 임상에서 널리 쓰이고 있다. 그 중 Alendronate는 Aminobisphosphonates의 한 종류로 non-aminobisphosphonates인 etidronate보다 100-1000배 더 강한 효과를 보이는 것으로 알려져 있다. 본 실험의 목적은 백서두개골 결손부의 골재생을 실험모델로 하여 alendronate의 국소투여 효과를 알아보는 것으로 액체의 흡수성과 골전도성이 우수한 것으로 알려진 collagen membrane을 사용하여 결손부 양측에 alendronate와 physiologic saline을 각각 적용하여 1주, 2주, 4주의 조직학적 치유양상, 파골세포활성도, 경도를 평가하였다. 조직학적 치유양상은 1주째 collagen membrane에 의한 염증성 침윤이 나타났으며 2주째부터 골성회복이 관찰되었고 4주째 완전한 골성회복을 보여 각주별 실험군, 대조군 공히 유사한 양상을 보였고 실험에 사용한 $200{\mu}g$의 용량은 조직학적으로 관찰할만한 골재생의 향상을 위해서는 부족한 용량으로 사료되는 바이다. TRAP(+) cell은 1주째 대조군에 비해 실험군에서 유의하게 적은 수를 보였으며(p<0.01) 2주와 4주째는 유의한 차이를 나타내지 않았고 경도측정에서는 2주째 대조군에 비해 실험군에서 유의하게 높은 경도를 보였으며 4주째 유의한 차이를 나타내지 않았다(p<0.05). 이상의 실험에서 alendronate는 골조직 치유과정의 초기에 파골세포의 활성도와 경도에 다소 영향을 미친 것으로 사료되며 향후 골조직 재생을 위한 임상적용에 응용을 위해서는 치유과정을 더욱 향상시킬 수 있는 추가적인 연구가 필요하리라 사료된다.

Keywords

References

  1. Fleisch H., Russel RGG., Bisaz S., Muhlbauer R. C., and Willliams D. A. : The inhibitory effect of phosphonates on the formation of calcium phosphonate crystals in vitro and aortic and kidney calcification in vivo, Eur. J. Clin. Invest., 1:12-18, 1970
  2. Hansen N. M., Felix R., Bisaz S. and Fleisch H. : Aggregation of hydroxyapatite crystals, Biochem. Biophys. Acta., 451:549-559, 1976
  3. Fleisch H. and Bisaz S. : Mechanism of action of the bisphosphonates, Medicina. 57 Suppl., 1:65-75, 1997
  4. Porras A. G., Sherry D. Holland and Barry J. Gertz. : Pharmacokinetics of Alendronate, Clin. Pharmacokinet., 36:315-328, 1999
  5. Chestnut C. H., McClung M. R., Ensrud K. : Alendronate treatment of postmenopausal osteoporotic women : effect of multiple dosages on bone mass and bone remodeling, Am. J. Med., 99:144-52,1995
  6. Jeal W., Barradell L. B., and McTavish D. : Alendronate. A review of its pharmacological properties and therapeutic efficacy in postmenopausal osteoporosis, Drugs., 53:415-34, 1997
  7. Sparidans R. W., Twiss I. M., Talbot S., : Bisphosphonates in bone diseases, Pharm, World. Sci., 20:206-13, 1998
  8. Jung A. : Comparison of two parenteral diphosphonates in hypercalcemia of malignancy, Am. J. Med., 72:221-226, 1982
  9. Adami S. and Zamberlan N. : Adverse effects of bisphosphonates. A comparative review, Drug. Saf., 14:158-70, 1999 https://doi.org/10.2165/00002018-199614030-00003
  10. Porras A. G., Sherry D. H. and Barry J. G. : Pharmacokinetics of Alendronate. Clin Pharmacokinet. 35:315-328, 1999
  11. Michael A. B., Eros S. C., Kenneth S. K., Thomas B. A. and Robert W. : Effects of a bisphosphonate on experimental periodontitis in monkeys, J. Periodontol., 63:825-830, 1992
  12. Yaffe A., Nachum F., Ido A. and Iyzhak B. : The effect of bisphosphonate on alveolar bone resorption following mucoperiosteal flap surgery in the mandible of rats, J. Periodontol., 66:999-1003,1995
  13. Yaffe A., Iztkovich M., Earon Y., I, AIt, R. Lilov and I. Binderman : Local delivery of an amino bisphosphonate prevents the resorptive phase of alveolar bone following mucoperiosteal flap surgery in rats, J. Periodontol., 68:884-889, 1997
  14. Stephen J. M., Charles M. R., Peter C. W. : Use of alendronate in peri-implant defect healing, J. Periodontol., 70:151-158, 1999
  15. Carles B., Birte M. and Karin V. : Improtance of the Critical-size Bone Defect in Testing Bone-Regenerating Materials, J. Craniofac. Surg. 9(4):310-316, 1998
  16. Deporter, D. A., Komori, N., Howley, T. P., Tomar A. : Reconstituted bovine skin collagen enhances healing of bone wounds in the rat calvaria, Calcif. Tissue. Int., 42:321-325
  17. AIdo C., Steven L. T., John D. K., Paul H. S. and Harty C. B. : Bisphosphonates directly inhibit the bone resoption activity of isolated osteoclasts in vitro. J. Clin. Invest., 456-461, 1990
  18. David. E. H., MacDonald B. R., Russel R. G. G. and Gowen M. : Inhibition of osteoclast-like cell formation by bisphosphonates in lont-term cultures of human bone marrow, J. Clin. Invest., 83:1930-1935, 1989
  19. David E. H., Kenneth R. W., Harty L. U., Akira S., David G. R., Gregory R. M. and Brendan F. B. : Bisphosphonates romote Apoptosis in murine osteoclasts in vitro and in vivo, J. Bone. Miner. Res., 10:1478-1487, 1995
  20. Selander K. S., Monkkonen J., Karhukorpi E. K., Harkonen P., Hannunimi R. and Vananen H. K. : Characteristics of clodronate-induced apoptosis in oscteoclasts and macrophages, Mol. Pharmacol., 50:1227-1138, 1996
  21. Murakami H., Takahashi N., Tanaka S., Nakamura I., Udagawa N., Nakajo S., Nakaya K., Abe M., Yuda Y., Konno F., Barbier A. and Suda T. : Tiludronate inhibits Protein Tyronsine Phosphatase activity in osteoclasts, Bone., 20:399-404, 1997
  22. Murakami H., Hakahashi N., Sasaki T., Udagawa N., Tanaka S., Nakamura I., Zhang D., Babier A. and Soda T. : A possible mechanism of the specific action of bisphosphonates on osteoclasts : Tiludronate preferentially affects polarized osteoclasts having ruffled borders, Bone., 17:137-144, 1995
  23. Selander K. S., Monkkonen J., Karhukorpi E. K., Harkonen P., Hannunimi R. and Vananen H. K. : Characteristics of clodronate-induced apoptosis in oscteoclasts and macrophages, Mol. Pharmacol., 50:1227-1138, 1996
  24. Steven P. L., David E. H., Fraser P. C., Graham G. R. and Michael J. R. : Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins including ras, J. Bone. Miner. Res., 13:581-589, 1998
  25. Nishikawa M., Adatsu T., Katayama Y., Yasutomo Y., Kado S., Kugai N., Yamamoto M. and Nagata N. : Bisphosphonates act on Osteoblastic cells and inhibit osteoclast formation in Mouse marroe cultures, Bone., 18:9-14, 1996
  26. Claire V., Fleisch H., Turin K. and Harald L. : Bisphosphonates induce osteoblasts to secrete an inhibitor of Osteoclast-mediated resorption, Endocrinology., 137:2324-2333, 1996
  27. Kim : The Effect of Fibrillar Collagen on bony Healing of Calvarial Defect in Rats, J. Kor. Acad, ' Periodontol., 29:355-370, 1999
  28. Ripamonti U., Schnizler C. M. and Cleaton-Jones P. C. : Bone induction in a Composite allogenic bone/alloplastic implant, Int. J. Oral. Maxillofac. Surg. 47:963-969, 1989
  29. Adachi K., Igarashi H. and Mitani H. S. : Effects of Topical Administration of a Bisphosphonate on Orthodontic Tooth Movements in Rats, J. Dent. Res., 73:1478-1484, 1994
  30. Denissen H., van Beek E., Lowik C., Papapoulos S. and van den Hooff A. : Ceramic hydroxyapatite implants for the release of bisphosphonate, Bone. Miner., 25:123-134, 1994
  31. Tsuchimoto M., Azuma Y. and Higuchi O. : Alendronate modulates osteogenesis of human osteoblastic cells in vitro, Jpn. J. Pharmacol., 66:25-23, 1994
  32. Yaffe A., Binderman E. and Breuer T. P. : Disposition of Alendronate Following Local Delivery in a Rat Jaw, J. Periodontol., 70:893-895, 1999
  33. Binderman M. A. and Yaffe A. : Effectiveness of Local Delivery of Alendronate in Reducing Alveolar Bone Loss Following Periodontal Surgery in Rats, J. Periodontol., 71:1236-1240, 2000
  34. Moon : The Effects of Alendronate on healing of the Extraction sockets in Rats, J. Kor. Acad. Periodontol., In press
  35. Motoie H., Okazaki A., Kanoh H., Shikama H. and Fujikura T. : Increase of bone mass and mechanical strength in rats after treatment with a novel bisphosphonate, YM175, for two years, Pharmacology & Toxicology., 81:42-47, 1997